SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Ovarian Cancer: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Ovarian Cancer.

What the end of affirmative action means to a fourth-year medical student

When the U.S. Supreme Court released its landmark ruling overturning the use of race-conscious college admissions, LaShyra Nolen was on clinical rotation. For Nolen, a

July 3, 2023

Researchers unlock potential of light-controlled cellular activities

Researchers at the Paul Scherrer Institute PSI have succeeded in elucidating the structure of specific photoreceptors.

October 25, 2024

Study links air pollution and limited green spaces to higher respiratory hospitalization risk

Long-term exposure to air pollution and a lack of access to green spaces increases the risk of hospitalization for respiratory conditions, according to a study

September 9, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.